tetano
Editor, Senior Moderator
Nat Commun
. 2020 Aug 14;11(1):4081.
doi: 10.1038/s41467-020-17972-1.
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
Shipo Wu[SUP] 1 [/SUP], Gongxun Zhong[SUP] 2 [/SUP], Jun Zhang[SUP] 1 [/SUP], Lei Shuai[SUP] 2 [/SUP], Zhe Zhang[SUP] 1 [/SUP], Zhiyuan Wen[SUP] 2 [/SUP], Busen Wang[SUP] 1 [/SUP], Zhenghao Zhao[SUP] 1 [/SUP], Xiaohong Song[SUP] 1 [/SUP], Yi Chen[SUP] 1 [/SUP], Renqiang Liu[SUP] 2 [/SUP], Ling Fu[SUP] 1 [/SUP], Jinlong Zhang[SUP] 1 [/SUP], Qiang Guo[SUP] 1 [/SUP], Chong Wang[SUP] 2 [/SUP], Yilong Yang[SUP] 1 [/SUP], Ting Fang[SUP] 1 [/SUP], Peng Lv[SUP] 1 [/SUP], Jinliang Wang[SUP] 2 [/SUP], Junjie Xu[SUP] 1 [/SUP], Jianmin Li[SUP] 1 [/SUP], Changming Yu[SUP] 1 [/SUP], Lihua Hou[SUP] 3 [/SUP], Zhigao Bu[SUP] 4 [/SUP], Wei Chen[SUP] 5 [/SUP]
Affiliations
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.
. 2020 Aug 14;11(1):4081.
doi: 10.1038/s41467-020-17972-1.
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
Shipo Wu[SUP] 1 [/SUP], Gongxun Zhong[SUP] 2 [/SUP], Jun Zhang[SUP] 1 [/SUP], Lei Shuai[SUP] 2 [/SUP], Zhe Zhang[SUP] 1 [/SUP], Zhiyuan Wen[SUP] 2 [/SUP], Busen Wang[SUP] 1 [/SUP], Zhenghao Zhao[SUP] 1 [/SUP], Xiaohong Song[SUP] 1 [/SUP], Yi Chen[SUP] 1 [/SUP], Renqiang Liu[SUP] 2 [/SUP], Ling Fu[SUP] 1 [/SUP], Jinlong Zhang[SUP] 1 [/SUP], Qiang Guo[SUP] 1 [/SUP], Chong Wang[SUP] 2 [/SUP], Yilong Yang[SUP] 1 [/SUP], Ting Fang[SUP] 1 [/SUP], Peng Lv[SUP] 1 [/SUP], Jinliang Wang[SUP] 2 [/SUP], Junjie Xu[SUP] 1 [/SUP], Jianmin Li[SUP] 1 [/SUP], Changming Yu[SUP] 1 [/SUP], Lihua Hou[SUP] 3 [/SUP], Zhigao Bu[SUP] 4 [/SUP], Wei Chen[SUP] 5 [/SUP]
Affiliations
- PMID: 32796842
- DOI: 10.1038/s41467-020-17972-1
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.